San Diego-based Viking Therapeutics marked alone as a significant competitor in the weight loss drug sector in February soon after revealing promising details from a mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given like a weekly injection and in March the company unveiled